Last Updated : September 22, 2014
Details
FilesGeneric Name:
Omalizumab
Project Status:
Complete
Therapeutic Area:
Chronic idiopathic urticaria
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Xolair
Project Line:
Reimbursement Review
Project Number:
SR0398-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Not achieved
Submission Type:
Initial
Indications:
Urticaria, chronic idiopathic
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : September 22, 2014